ArticleJournal of neuroinflammation2026
Hepatic Orosomucoid 2 aggravates demyelination and drives microglial DAM-like activation.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionDemyelination is a central pathological feature of white matter injury (WMI). Emerging evidence suggests that hepatokines act as systemic regulators of brain pathology, raising the possibility that liver-derived signals contribute to WMI. Here, we investigated whether hepatokine Orosomucoid 2 (ORM2) aggravates demyelination through liver-brain communication by modulating disease-associated microglia (DAM)-like activation in WMI.
methodsORM2 expression was assessed in the cuprizone (CPZ) demyelination model using RNA sequencing, quantitative PCR, western blotting, and immunofluorescence. The functional role of ORM2 in WMI was examined using ORM2 knockout mice, hepatocyte-specific ORM2 transgenic mice, and hepatocyte-targeted ORM2 knockdown strategies, combined with behavioral analyses and histological evaluation of myelin integrity. Transcriptomic profiling, lipid staining, and microglial phenotyping were performed to characterize DAM-associated responses.
resultsCPZ-induced demyelinating challenge was accompanied by robust hepatic ORM2 induction and increased cerebral ORM2 protein accumulation. Flag-tagged ORM2 tracing showed that hepatocyte-derived ORM2 could be detected in the injured brain after CPZ-induced white matter injury. ORM2 deficiency alleviated, whereas hepatocyte-specific ORM2 overexpression exacerbated, demyelination and behavioral deficits. Hepatocyte-targeted knockdown of ORM2 reduced cerebral ORM2 accumulation and mitigated white matter pathology, supporting a peripheral contribution of hepatic ORM2 to WMI. Transcriptomic and histological analyses revealed that ORM2 promoted inflammatory and DAM-like microglial programs. Mechanistically, ORM2 promoted activation of the SYK-PLCγ2 signaling axis, thereby driving DAM-like activation, lipid-associated dysregulation, and myelin loss.
conclusionsOur findings identify hepatic ORM2 as a pro-inflammatory hepatokine that aggravates WMI through liver-brain communication. By enhancing SYK-PLCγ2 signaling and driving DAM-like microglial activation, ORM2 links peripheral hepatic stress to central demyelination, highlighting hepatic ORM2 as a potential therapeutic target for white matter disorders.
Indexed as
Identifiers
42919384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.